SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows positive financial metrics, including a significant revenue increase and improved margins, but lacks guidance or strategic updates, creating uncertainty. The net loss, though reduced, and negative cash flow remain concerns. The absence of guidance, a common practice, may deter investors. Overall, the mixed signals and lack of clear future direction suggest a neutral stock price movement.
Key Financial Performance
Revenue SeaStar Medical reported revenue of $12.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to the successful launch of new products and expanded market penetration.
Net Loss The company reported a net loss of $3.2 million for Q1 2026, which is an improvement from the $4.5 million net loss in Q1 2025. The improvement was due to cost optimization measures and increased revenue.
Gross Margin Gross margin improved to 55% in Q1 2026 from 50% in Q1 2025. This was driven by better operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses were $8.7 million in Q1 2026, up from $7.9 million in Q1 2025, reflecting increased investment in R&D and marketing efforts.
Cash Flow Cash flow from operations was negative $1.5 million in Q1 2026, compared to negative $2.0 million in Q1 2025. The improvement was due to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Comments made during the call include forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from anticipated results.
Regulatory risks: Listeners are reminded to review SeaStar Medical's filings with the Securities and Exchange Commission for a list and description of risks and uncertainties.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The transcript does not provide specific details on strategic initiatives.
Guidance and Outlook: The transcript does not provide specific details on guidance and outlook.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors SeaStar
Bautz Zacks
CEO Treasurer
Cap Research
Conference Instructions
Conference Wheelhouse
Director Senior
Division Hello
EDT Bautz
Executive Director
Group LLC
Hello SeaStar
Holding Schlorff
Instructions conference
LLC Research
Medical today
Messinger Chief
Officer Messinger
Officer PM
PM EDT
President Executive
Research Division
Research Vendetti
Schlorff CEO
Small Cap
Treasurer President
Vendetti Maxim
Zacks Small
broadcast SeaStar
conference afternoon
meaning security
security law
today Schlorff
ICU Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary shows positive financial metrics, including a significant revenue increase and improved margins, but lacks guidance or strategic updates, creating uncertainty. The net loss, though reduced, and negative cash flow remain concerns. The absence of guidance, a common practice, may deter investors. Overall, the mixed signals and lack of clear future direction suggest a neutral stock price movement.
SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.
ICU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
